Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial
Oslo, Norway, 19 November 2020 Nordic Nanovector ASA (OSE: NANO) announces that it enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 (LYMRIT 37-07) trial investigating safety and preliminary efficacy of Betalutin® ([177]Lu lilotomab satetraxetan) in combination with rituximab in 2[nd]-line follicular lymphoma (2L FL). The dosing regimen in this cohort is a single administration of 15 MBq/kg Betalutin® preceded by 40mg lilotomab, followed by 375 mg/m[2] rituximab once per week for four weeks. Data from this cohort is expected in H1’2021 and will